Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 11:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ketamine hydrochloride injection Clear all
Suspended Phase 4 Interventional

IM Ketamine vs Midazolam for Suicidal ER Patients

NCT04640636
View directory record Official record
Conditions
Depression, Unipolar, Depression, Bipolar, Suicidal Ideation
Interventions
Ketamine hydrochloride injection, Midazolam injection
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 25, 2026, 11:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets

NCT05046184
View directory record Official record
Conditions
Major Depressive Disorder, Healthy Controls
Interventions
Ketamine Hydrochloride, Midazolam injection
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Sep 25, 2026, 11:42 PM EDT
Completed Phase 2 Interventional Results available

Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients

NCT02935595
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Ketamine
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Sep 25, 2026, 11:42 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Intravenous Ketamine in the Treatment of Obsessive-Compulsive Disorder

NCT01371110
View directory record Official record
Conditions
Obsessive Compulsive Disorder
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Wayne Goodman MD
Other
Eligibility
21 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Sep 25, 2026, 11:42 PM EDT
Terminated Phase 2 Interventional Results available

KAP for Depression in Abstinent Opioid Users

NCT05193318
View directory record Official record
Conditions
Opioid Use Disorder, Severe, in Sustained Remission, Opioid Use Disorder, Severe, in Early Remission, Major Depressive Disorder
Interventions
Ketamine-assisted psychotherapy
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 64 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2024 · Synced Sep 25, 2026, 11:42 PM EDT
Terminated Phase 3 Interventional

Perioperative Analgesia on Postoperative Opioid Usage and Pain Control in H&N Cancer Surgery

NCT04176419
View directory record Official record
Conditions
Postoperative Pain Control, Opioid Consumption
Interventions
Ketamine, Placebo Ketamine, Lidocaine, Placebo Lidocaine, Acetaminophen, Placebo Acetaminophen, Gabapentin, Placebo Gabapentin, Celecoxib, Placebo Celecoxib
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 25, 2026, 11:42 PM EDT
Recruiting Phase 2 Interventional

Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients

NCT07639359
View directory record Official record
Conditions
Critical Illness, Depressive Symptoms
Interventions
Ketamine (0.5 mg/kg), Normal Saline (0.9% NaCl)
Drug · Other
Lead sponsor
Hospital Italiano de Buenos Aires
Other
Eligibility
18 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 25, 2026, 11:42 PM EDT
Not yet recruiting Phase 3 Interventional

Optimal Timing of Ketamine Initiation for SCD Pain

NCT07450430
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Crisis
Interventions
Ketamine hydrochloride injection, Placebo
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years to 24 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 25, 2026, 11:42 PM EDT
Terminated Phase 1 Interventional

A Pilot Clinical Trial of Oral Ketamine for Acute Pain Management After Amputation Surgery

NCT02341963
View directory record Official record
Conditions
Acute Pain Management, Analgesic, Nonopioid, Amputation of Lower Extremity, All Causes
Interventions
Oral Ketamine
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 28, 2021 · Synced Sep 25, 2026, 11:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of Two Intravenous Drug Combinations for Ambulatory Oral & Maxillofacial Surgery

NCT06867068
View directory record Official record
Conditions
Anesthesia, Tooth Extraction
Interventions
Midazolam Hydrochloride, Fentanyl, Ketamine, Propofol injection, Nitrous oxide
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
16 Years and older
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 25, 2026, 11:42 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Hematoma Block as an Adjunct to Procedural Sedation for Forearm Fracture Reduction

NCT00763880
View directory record Official record
Conditions
Forearm Fracture
Interventions
Lidocaine, Saline
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
3 Years to 17 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Sep 25, 2026, 11:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ketamine for Suicidality in Bipolar Depression

NCT01944293
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Episode, Suicidal Ideation
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Sep 25, 2026, 11:42 PM EDT
Recruiting Phase 2Phase 3 Interventional

Ketamine & Crisis Response Plan for Suicidal Ideation in the ED

NCT05696691
View directory record Official record
Conditions
Suicide
Interventions
Ketamine Hydrochloride, Crisis Response Plan
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Sep 25, 2026, 11:42 PM EDT
Completed Phase 2 Interventional

Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV

NCT06538285
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Ketamine, Psychotherapy
Drug · Behavioral
Lead sponsor
Nicky Mehtani, MD, MPH
Other
Eligibility
18 Years to 69 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francicso, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 25, 2026, 11:42 PM EDT
Completed Early Phase 1 Interventional Results available

Inpatient Single Dose Interventions for Alcohol Use Disorder

NCT04562779
View directory record Official record
Conditions
Alcohol Use Disorder, Severe
Interventions
Naltrexone 380 MG, Ketamine Hydrochloride, Enhanced linkage
Drug · Behavioral
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Sep 25, 2026, 11:42 PM EDT
Recruiting Phase 2 Interventional

Pragmatic Trial of Psilocybin Therapy in Palliative Care

NCT05403086
View directory record Official record
Conditions
Demoralization
Interventions
Psilocybin, Ketamine
Drug
Lead sponsor
Charles S. Grob, M.D.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Greenbrae, California • Los Angeles, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 25, 2026, 11:42 PM EDT
Terminated Phase 2Phase 3 Interventional

Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder

NCT01504659
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Ketamine hydrochloride injection, Flat tonic water (e.g., Canada Dry Tonic Water)
Drug
Lead sponsor
Juvenile Bipolar Research Foundation
Other
Eligibility
6 Years to 12 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Not Predetermined, Connecticut • Maplewood, New Jersey • Not Predetermined, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 25, 2026, 11:42 PM EDT
Not yet recruiting Phase 2 Interventional

Ketamine-Assisted Psychotherapy for Treatment-Resistant Depression

NCT07247006
View directory record Official record
Conditions
Treatment Resistant Depression (TRD), Chronic Pain
Interventions
Ketamine hydrochloride injection
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 25, 2026, 11:42 PM EDT
Completed Phase 4 Interventional Results available

Ketamine in the Treatment of Suicidal Depression

NCT01700829
View directory record Official record
Conditions
Major Depressive Disorder, Suicidal Ideation
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Sep 25, 2026, 11:42 PM EDT